Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

The City’s legal professional body has said it is on standby to support Weil Gotshal and Manges trainees as the storied US law firm prepares to wind down after 95 years. Colin Passmore, chairman of the City of London Law Society (CLLS), said: “Our primary concern is everyone at Weil’s office, particularly the trainees and [...]

Cellectis (CLLS) presented preclinical data for .HEAL-101, its gene-editing candidate for severe hypertriglyceridemia, at the European Society of Gene and Cell Therapy congress.The candidate targets APOC3, a driver of elevated triglycerides. In human liver cells, mean editing was approximately 90%, without DNA double-strand breaks at the target site. In mice with humanized livers and normal lipid levels, a single intravenous injection achieved approximately 65% mean human APOC3 editing, reaching up to 70%. In a separate mouse disease model, APOC3 fell 67% ± 12% (mean ± standard deviation); single-dose triglyceride reduction was highlighted at 76%. Editing was detected in the liver, with no significant activity in other tissues analyzed.Cellectis plans a Phase 1 investigator-initiated trial in China, with preliminary clinical data expected in the second half of 2027.

Dans le point d'actualités avec Jamila El Bougrini, analyste biotech chez Invest Securities, on revient sur Medincell, ArgenX et on fait le point sur les avancées et les promesses de l'IA dans l'innov...

Pomerantz LLP is currently investigating potential securities fraud involving Cellectis S.A. after a significant drop in its stock price following recent announcements.

Cellectis (CLLS) reported its monthly share capital and voting rights totals as of September 30, 2026.The company had 100,732,781 shares in its capital and 105,563,044 voting rights on that date. The disclosure falls under Article 223-16 of the French financial markets authority’s General Regulation.

Citizens cut Cellectis to Market Perform after it scrapped allogeneic CAR-T programs and pivoted to in-vivo gene editing for high triglycerides and cholesterol. Catalysts now 2027–28.